Dr. du Bois on Study of Secondary Cytoreductive Surgery in Ovarian Cancer

Video

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

In a randomized controlled phase III study, investigators evaluated the impact of secondary cytoreductive surgery in patients with recurrent ovarian cancer.

Related Videos
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Erin K. Crane, MD, MPH
Omid Hamid, MD
Eric Vallieres, MD, FRCSC
Josep Maria Piulats Rodriguez, MD, PhD
Samer A. Srour, MB ChB, MS
William B. Pearse, MD
Núria Agustí Garcia, MD
Mikkael A. Sekeres, MD, MS
Benjamin Levy, MD
Related Content
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, consultant medical oncologist, Guy’s and St Thomas’ NHS Foundation Trust, NIHR Guy’s Clinical Research Facility

First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer

April 14th 2024
Article
Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

April 20th 2023
Podcast
Debra L. Richardson, MD, FACS, FACOG, associate professor, chief, Section of Gynecologic Oncology and Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma (OU) College of Medicine, OU Health

Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer

April 4th 2024
Article
Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

July 18th 2022
Podcast
Susana N. Banerjee, MBBS, MA, PhD, FRCP, The Royal Marsden NHS Foundation Trust

Avutometinib Plus Defactinib Shows High Response Rates in Heavily Treated LGSOC

March 21st 2024
Article
3d illustration of ovarian cancer | Image Credit: © Lars Neumann - stock.adobe.com

ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer

March 20th 2024
Article